Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 983 of 6351
-
New combo therapy aims to keep high-risk neuroblastoma from coming back
Disease control OngoingThis phase II trial studies if dinutuximab, GM-CSF, isotretinoin in combination with irinotecan, and temozolomide (chemo-immunotherapy) can be given safely to patients with high-risk neuroblastoma after Consolidation therapy (which usually consists of two autologous stem cell tra…
Phase 2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug A140 challenges standard treatment for colorectal cancer
Disease control CompletedCompare the objective remission rate of A140 and Erbitux combined with mfolfox6 regimen in the first-line treatment of Ras wild-type metastatic colorectal cancer for 12 weeks
Phase 3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
DNA vaccine against COVID-19 shows promise in early trial
Vaccine CompletedThis clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) in healthy volunteers.
Phase 1/2 • Sponsor: GeneOne Life Science, Inc. • Aim: Vaccine
Last updated Jun 26, 2026 12:56 UTC
-
Can a pill combo keep melanoma from coming back?
Disease control OngoingThis is a prospective, open label, single-arm, multicenter, non-interventional study of dabrafenib in combination with trametinib as adjuvant treatment for Chinese patients with stage III BRAF V600 mutation positive melanoma after complete resection.
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental combo shows promise for Hard-to-Treat melanoma
Disease control CompletedThis is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab. The study will enroll patients with advanced and/or metastatic melanoma that h…
Phase 2 • Sponsor: Highlight Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Immunotherapy cocktail aims to boost breast cancer remission before surgery
Disease control OngoingThis is a Phase II, randomized, open-label trial to evaluate the clinical and immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple negative breast cancer (TNBC).
Phase 2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Injections vs. scalpel: which straightens Peyronie's curvature better?
Disease control OngoingThe purpose of this study is to compare key clinical outcomes of collagenase clostridium histolyticum injections versus surgery for the management of Peyronie's Disease.
Phase 4 • Sponsor: Charitable Union for the Research and Education of Peyronie's Disease • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New blood test aims to detect colon cancer early
Diagnosis Recruiting nowA prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
Sponsor: Universal Diagnostics • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC
-
New drug cocktail targets tough blood cancers
Disease control Recruiting nowThis phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has IDH1 mutation. The safety of this drug combination will also be studied. IDH1 is a type of genetic mutation (chang…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New combo therapy aims to tame tough prostate cancer
Disease control OngoingThis phase II trial studies the effect of cabazitaxel, carboplatin, and cetrelimab followed by niraparib with or without cetrelimab in treating patients with aggressive variant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as c…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 09, 2026 23:00 UTC
-
New drug cocktail aims to outsmart advanced breast cancer
Disease control OngoingDESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New combo aims to outsmart lung Cancer's growth signals
Disease control Recruiting nowThis phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is in…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could a COVID-19 shot boost cancer immunotherapy? a massive study digs into the timing.
Knowledge-focused OngoingCOVICI-SURV is a nationwide, retrospective observational cohort study using the French national health data system (SNDS) to evaluate whether COVID-19 vaccination, particularly mRNA vaccination, received within 100 days before or after immune checkpoint inhibitor (ICI) initiation…
Sponsor: Groupe Hospitalier Pitie-Salpetriere • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
New combo therapy aims to stop rare HER2-positive salivary gland cancer in its tracks
Disease control Recruiting nowThis research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of st…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Brain surgery boost: radioactive seeds may keep tumors from returning
Disease control OngoingThe purpose of this study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after sur…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Second chance: new combo targets relapsed CLL after venetoclax fails
Disease control Recruiting nowFixed-duration regimens containing combinations of venetoclax with CD20 targeting agents are expected to soon become standard practice in first-line patients with chronic lymfocytic leukemia (CLL). The advantage of a fixed duration venetoclax combination as part of first-line tre…
Phase 2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New combo therapy aims to tame recurrent head and neck cancer
Disease control OngoingThe purpose of this study is to test the safety of palliative "QUAD SHOT" radiotherapy combined with pembrolizumab and evaluate the effects of the combination treatment patients with recurrent cancer of head and neck.
Phase 2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Radiation 'Re-Priming' could supercharge CAR-T therapy in stubborn lymphoma
Disease control CompletedThis is a single-arm open-label phase I/II trial studying the safety and efficacy of focal 're-priming' radiation therapy (RT) to FDG-avid residual sites of disease in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) patients with incomplete response (IR) to CAR T-cell therapy …
Phase 1/2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo may keep breast cancer from coming back
Disease control OngoingPOETIC-A is a phase 3 trial which targets post-menopausal primary breast cancer patients with a high 5-year risk of relapse as determined by a high Ki67 after 2 weeks aromatase inhibitor therapy pre-surgery. Eligible patients will be randomised to standard adjuvant endocrine ther…
Phase 3 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Which therapy works best for kids with MIS-C?
Disease control CompletedIn March 2020, children exposed to the virus that causes the COVID-19 illness, SARS-CoV-2, presented with fever and significant inflammation about a month after exposure to the virus. Some children were sick enough to require care in the intensive care unit for what came to be kn…
Phase 2/3 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC